Page last updated: 2024-08-22

holmium and dutasteride

holmium has been researched along with dutasteride in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Antonini, G; Busetto, GM; Corsi, P; D'Agostino, D; De Berardinis, E; De Cobelli, O; Del Giudice, F; Del Rosso, A; Ferro, M; Giampaoli, M; Lucarelli, G; Maggi, M; Palmer, K; Porreca, A; Romagnoli, D; Sciarra, A; Terracciano, D	1

Trials

1 trial(s) available for holmium and dutasteride

Article	Year
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity. Aging, 2020, 03-11, Volume: 12, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Blood Loss, Surgical; Double-Blind Method; Dutasteride; Holmium; Humans; Lasers, Solid-State; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Treatment Outcome; Vascular Endothelial Growth Factor A	2020

Article

Year

Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity.

Aging, 2020, 03-11, Volume: 12, Issue:5

Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Blood Loss, Surgical; Double-Blind Method; Dutasteride; Holmium; Humans; Lasers, Solid-State; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Treatment Outcome; Vascular Endothelial Growth Factor A

2020